Shop
Lorlatinib / Lorbrena (Everest)
Original price was: £409.00.£347.00Current price is: £347.00.Lorlatinib (also known as Lorlatinib; Brand name: Lorbrena) is a third-generation ALK and ROS1 tyrosine kinase inhibitor (TKI) with broad coverage against ALK resistance mutations and strong central nervous system (CNS) penetration.
Lorlatinib demonstrates potent activity against resistance mutations that develop after treatment with crizotinib and second-generation ALK inhibitors, making it an important targeted therapy option for advanced ALK-positive non-small cell lung cancer (NSCLC).
MedFind provides overseas sourcing services for Lorlatinib through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Venetoclax / Venclexta (Everest)
Original price was: £300.00.£256.00Current price is: £256.00.Venetoclax (also known as Venetoclax; Brand name: Venclexta) is the first selective targeted therapy designed to inhibit the B-cell lymphoma-2 (BCL-2) protein, helping promote apoptosis in cancer cells and suppress tumor survival.
MedFind provides overseas sourcing services for Venetoclax through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Ponatinib (Everest)
Price range: £174.00 through £312.00Ponatinib (Brand name: ICLUSIG) is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI) used for the treatment of chronic myeloid leukemia (CML) with the ABL T315I mutation and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
It is also indicated for patients with CML or ALL who are resistant to or intolerant of previous tyrosine kinase inhibitor therapies.
MedFind provides overseas sourcing services for Ponatinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Adagrasib (Everest)
Original price was: £512.00.£461.00Current price is: £461.00.Adagrasib (Brand name: Krazati) is an FDA-approved KRAS G12C targeted therapy indicated for the treatment of advanced non-small cell lung cancer (NSCLC).
It is the second KRAS G12C inhibitor approved following sotorasib and has demonstrated activity in certain patients who developed resistance to previous KRAS-targeted therapies.
MedFind provides overseas sourcing services for Adagrasib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process, along with authenticity assurance and fast shipment availability.
Avatrombopag (Everest)
Original price was: £208.00.£182.00Current price is: £182.00.Avatrombopag (Avatrombopag) is an oral thrombopoietin receptor agonist (TPO-RA) designed to stimulate bone marrow platelet production and help reduce the risk of bleeding caused by thrombocytopenia.
MedFind provides overseas sourcing services for Avatrombopag through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Supports platelet recovery for patients with low platelet counts before surgery and those with chronic immune thrombocytopenia (ITP), with product authenticity assurance, fast shipment availability, and professional consultation support.
Gilteritinib / Xospata (Everest)
Original price was: £412.00.£396.00Current price is: £396.00.Gilteritinib (Brand name: Xospata) is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor approved for the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations.
It is also being actively studied in multiple clinical trials for additional AML subtypes and combination treatment strategies, including first-line therapy, maintenance therapy, and use in combination with chemotherapy or other targeted therapies.
MedFind provides overseas sourcing services for Gilteritinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Erdafitinib (Everest)
Original price was: £600.00.£499.00Current price is: £499.00.Erdafitinib (Brand name: Balversa) is an oral pan-FGFR tyrosine kinase inhibitor used for the treatment of patients with locally advanced or metastatic urothelial carcinoma carrying FGFR2 or FGFR3 genetic alterations, especially in cases where platinum-based chemotherapy has failed.
MedFind provides overseas sourcing services for Erdafitinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Osimertinib / Tagrisso (Everest)
Original price was: £108.00.£91.00Current price is: £91.00.Osimertinib (Brand name: Tagrisso) is a third-generation oral, irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI) originally developed by AstraZeneca under the research code AZD9291.
It is used for the treatment of advanced non-small cell lung cancer (NSCLC) and selectively targets both EGFR-sensitive mutations and the EGFR T790M resistance mutation.
Osimertinib (Tagrisso) received approval for import and clinical use in China in March 2017.
Ibrutinib / Ibrutinib Capsules / Imbruvica (Everest)
Original price was: £300.00.£249.00Current price is: £249.00.Ibrutinib (Brand name: Imbruvica) is an oral BTK inhibitor used for the treatment of relapsed mantle cell lymphoma (MCL), relapsed chronic lymphocytic leukemia (CLL), CLL with 17p deletion, and Waldenström’s macroglobulinemia (WM).
MedFind provides overseas sourcing services for Ibrutinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Capmatinib (Everest)
Original price was: £512.00.£429.00Current price is: £429.00.Capmatinib (Capmatinib) is a selective MET inhibitor used for the targeted treatment of patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. By inhibiting abnormal activation of the MET signaling pathway, Capmatinib helps effectively suppress tumor cell growth and spread.
Capmaxen by Everest Pharma is a high-quality generic version of Capmatinib, offering patients a more affordable treatment option. MedFind provides overseas sourcing services for Capmatinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.